Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply

Aliment Pharmacol Ther. 2021 Sep;54(6):848-849. doi: 10.1111/apt.16569.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adalimumab / adverse effects
  • Antibodies, Monoclonal
  • Crohn Disease*
  • Humans
  • Infliximab
  • Tumor Necrosis Factor Inhibitors*

Substances

  • Antibodies, Monoclonal
  • Tumor Necrosis Factor Inhibitors
  • Infliximab
  • Adalimumab